Posted by Michael Wonder on 23 Nov 2022
Blueprint Medicines submits supplemental new drug application to FDA for Ayvakit (avapritinib) for the treatment of indolent systemic mastocytosis
22 November 2022 - Blueprint Medicines today announced the submission of a supplemental new drug application to the US FDA for Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis.
Ayvakit was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of systemic mastocytosis in about 95% of cases.
